PMID- 22007905
OWN - NLM
STAT- MEDLINE
DCOM- 20120820
LR  - 20181201
IS  - 1468-3083 (Electronic)
IS  - 0926-9959 (Linking)
VI  - 26
IP  - 5
DP  - 2012 May
TI  - IgE-mediated allergy: a rare cause of chronic spontaneous urticarial with 
      allergen-specific immunotherapy as treatment option - a systematic review with 
      meta-analysis from China.
PG  - 533-44
LID - 10.1111/j.1468-3083.2011.04302.x [doi]
AB  - BACKGROUND: Allergen-specific immunotherapy (SIT) has long been a controversial 
      treatment for chronic urticaria (CU), although SIT has been used in patients with 
      allergic diseases for more than 90 years. OBJECTIVES: To evaluate the efficacy 
      and safety of SIT vs. conventional treatment (CT) in the treatment of CU. 
      METHODS: Systematic searches were conducted without language restrictions in 
      MEDLINE, EMBASE, the Cochrane Library, ISI Web of Knowledge, China National 
      Knowledge Infrastructure, and Chinese Scientific Journals Full Text Database. The 
      primary outcomes were efficacy and quality of life (QOL) and the secondary 
      outcomes were relapse rate and adverse events (AEs). RESULTS: Fourteen studies 
      (1838 patients) were included. None of them was double-blind placebo controlled. 
      Our study demonstrated that SIT seemed to show more clinical efficacy rate (OR 
      2.39; 95% CI, 1.73-3.30; I(2) = 55%, P = 0.008), more complete recovery rate (OR 
      2.13; 95% CI, 1.55-2.91; I(2) = 61%, P=0.008) and less relapse rate 2 weeks after 
      treatment (OR 0.38; 95% CI, 0.24-0.61; I(2) = 6%, P=0.20) than CT. Only one study 
      reported improved QOL and no study reported serious AEs after SIT. CONCLUSIONS: 
      Current evidence indicates that IgE-mediated allergy may be causative in a small 
      number of CU patients and specific immunotherapy with these allergens may be 
      beneficial in those patients. However, the number of included studies was small 
      and those qualities were low. So, available evidence is not adequate to draw an 
      affirmative conclusion and larger studies of high quality are needed to provide 
      increasingly convincing data and cases.
CI  - (c) 2011 The Authors. Journal of the European Academy of Dermatology and 
      Venereology (c) 2011 European Academy of Dermatology and Venereology.
FAU - Shi, C-R
AU  - Shi CR
AD  - First Hospital of Lanzhou University, Lanzhou, Gansu province, China.
FAU - Li, Y-P
AU  - Li YP
FAU - Luo, Y-J
AU  - Luo YJ
FAU - Shi, C-B
AU  - Shi CB
FAU - Yan, X
AU  - Yan X
FAU - Yang, K-H
AU  - Yang KH
FAU - Yi, K
AU  - Yi K
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20111018
PL  - England
TA  - J Eur Acad Dermatol Venereol
JT  - Journal of the European Academy of Dermatology and Venereology : JEADV
JID - 9216037
RN  - 0 (Allergens)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Allergens/*immunology
MH  - Child
MH  - Child, Preschool
MH  - Chronic Disease
MH  - Female
MH  - Humans
MH  - *Immunotherapy
MH  - Male
MH  - Middle Aged
MH  - Quality of Life
MH  - Urticaria/*immunology/therapy
MH  - Young Adult
EDAT- 2011/10/20 06:00
MHDA- 2012/08/21 06:00
CRDT- 2011/10/20 06:00
PHST- 2011/10/20 06:00 [entrez]
PHST- 2011/10/20 06:00 [pubmed]
PHST- 2012/08/21 06:00 [medline]
AID - 10.1111/j.1468-3083.2011.04302.x [doi]
PST - ppublish
SO  - J Eur Acad Dermatol Venereol. 2012 May;26(5):533-44. doi: 
      10.1111/j.1468-3083.2011.04302.x. Epub 2011 Oct 18.